FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Alembic receives EIR from USFDA for facility at Panelav
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Subscribe To Our Newsletter & Stay Updated